About Migco Pharmaceuticals
Migco Pharmaceuticals is focused on developing new drug therapies for the prevention and treatment of migraine headaches. Migco has clinical safety data for its lead compound MGX-008, a successful human concept trial and a clear path to market.
Missing: Migco Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Migco Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Migco Pharmaceuticals Frequently Asked Questions (FAQ)
When was Migco Pharmaceuticals founded?
Migco Pharmaceuticals was founded in 2004.
Where is Migco Pharmaceuticals's headquarters?
Migco Pharmaceuticals's headquarters is located at 8 Victoria Street, Rangiora.
What is Migco Pharmaceuticals's latest funding round?
Migco Pharmaceuticals's latest funding round is Other Investors.
Who are the investors of Migco Pharmaceuticals?
Investors of Migco Pharmaceuticals include Movac.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.